Literature DB >> 20542962

Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis.

D Wibisono, E Csernok, P Lamprecht, J U Holle, W L Gross, F Moosig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20542962     DOI： 10.1136/ard.2009.119172

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  23 in total

Review 1.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 3.  The role of necrotic cell death in the pathogenesis of immune mediated nephropathies.

Authors:  Neelakshi R Jog; Roberto Caricchio
Journal:  Clin Immunol       Date:  2014-05-17       Impact factor: 3.969

4.  Intrarenal Toll-like receptor 4 and Toll-like receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Kim M O'Sullivan; Sharon L Ford; Anthony Longano; A Richard Kitching; Stephen R Holdsworth
Journal:  Am J Physiol Renal Physiol       Date:  2018-06-20

Review 5.  Biomarkers in vasculitis.

Authors:  Paul A Monach
Journal:  Curr Opin Rheumatol       Date:  2014-01       Impact factor: 5.006

6.  High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations.

Authors:  Annette Bruchfeld; Mårten Wendt; Johan Bratt; Abdul R Qureshi; Sangeeta Chavan; Kevin J Tracey; Karin Palmblad; Iva Gunnarsson
Journal:  Mol Med       Date:  2010-09-10       Impact factor: 6.354

Review 7.  High-mobility group box 1 (HMGB1) in childhood: from bench to bedside.

Authors:  Valeria Chirico; Antonio Lacquaniti; Vincenzo Salpietro; Caterina Munafò; Maria Pia Calabrò; Michele Buemi; Teresa Arrigo; Carmelo Salpietro
Journal:  Eur J Pediatr       Date:  2014-05-09       Impact factor: 3.183

8.  Are urinary levels of high mobility group box 1 markers of active nephritis in anti-neutrophil cytoplasmic antibody-associated vasculitis?

Authors:  A W S de Souza; W H Abdulahad; P Sosicka; J Bijzet; P C Limburg; C A Stegeman; M Bijl; J Westra; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 10.  Recent developments in the role of high-mobility group box 1 in systemic lupus erythematosus.

Authors:  Fleur Schaper; Johanna Westra; Marc Bijl
Journal:  Mol Med       Date:  2014-03-13       Impact factor: 6.354
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.